Senores Pharma Announces 9th AGM on Sep 25, 2026
Senores Pharmaceuticals Limited will hold its 9th Annual General Meeting (AGM) on September 25, 2026. The meeting will be conducted via Video Conferencing/Other Audio-Visual Means. The announcement was published on August 27, 2026.
The announcement of an AGM is a standard corporate procedure and typically has a low impact on the company's stock price or business operations.
The announcement is a routine corporate event (AGM) and does not contain any specific financial or operational information that would suggest a positive or negative sentiment.
Senores Pharmaceuticals Limited has announced that its Ninth (9th) Annual General Meeting (AGM) will be held on Friday, September 25, 2026, at 11:30 AM IST. The meeting will be conducted through Video Conferencing / Other Audio-Visual Means (VC/OAVM).
This intimation was published in the Financial Express (English and Gujarati editions) on August 27, 2026. The notice of the AGM is also available on the company's website, www.senorespharma.com.
The company has complied with Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, by publishing this advertisement.
What to do with a filing like this
Senores Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Senores Pharmaceuticals Limited. Read the original for the full detail.